Modera Wealth Management LLC Sells 269 Shares of Hologic, Inc. (NASDAQ:HOLX)

Modera Wealth Management LLC lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,065 shares of the medical equipment provider’s stock after selling 269 shares during the quarter. Modera Wealth Management LLC’s holdings in Hologic were worth $1,446,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. Benson Investment Management Company Inc. purchased a new position in shares of Hologic in the 4th quarter worth approximately $4,832,000. Principal Financial Group Inc. lifted its holdings in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after acquiring an additional 1,606 shares during the period. Clean Yield Group boosted its position in Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares during the last quarter. Janus Henderson Group PLC grew its stake in Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Finally, Versor Investments LP purchased a new stake in shares of Hologic during the 3rd quarter valued at $1,677,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HOLX. Mizuho reduced their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday. UBS Group raised their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has an average rating of “Hold” and a consensus price target of $85.77.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $63.27 on Tuesday. The company has a 50 day moving average of $68.98 and a 200 day moving average of $75.78. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.20 billion, a P/E ratio of 19.96, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12 month low of $62.69 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.